AXSM – axsome therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting [Yahoo! Finance]
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $200.00 price target on the stock.
Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More [Yahoo! Finance]
Why Shares of Axsome Therapeutics Slumped Today [Yahoo! Finance]
Form 8-K Axsome Therapeutics, For: Apr 01
Form 8-K Axsome Therapeutics, For: Mar 25
Form 8-K Axsome Therapeutics, For: Mar 05
Form 8-K Axsome Therapeutics, For: Mar 03
Form 4 Axsome Therapeutics, For: Feb 21 Filed by: Mahony Susan
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.